However, in a recent trial of dapagliflozin in patients with confirmed and well-treated heart failure (DAPA-HF), SGLT2 inhibition reduced the risk of cardiovascular death and hospitalization for heart failure [2]. Here, SLC5A2 is linked to heart failure.